Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11402873 | PMC |
| http://dx.doi.org/10.5847/wjem.j.1920-8642.2024.084 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Case of Euglycemic Diabetic Ketoacidosis Associated With a Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor.
Cureus
December 2024
Family Medicine, Louisiana State University Health Sciences Center, Alexandria, USA.
Euglycemic diabetic ketoacidosis is a rare metabolic derangement seen in both type 1 and type 2 diabetes. Initially characterized decades ago, the prevalence of euglycemic diabetic ketoacidosis has increased in recent years following the introduction of sodium-glucose cotransporter-2 (SGLT2) inhibitors. Here, we present a case of euglycemic diabetic ketoacidosis associated with SGLT2 inhibitors.
View Article and Find Full Text PDFManagement, biomarkers and prognosis in people developing endocrinopathies associated with immune checkpoint inhibitors.
Nat Rev Endocrinol
January 2025
Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Immune-related adverse events (irAEs), including endocrine irAEs, can occur in response to cancer immunotherapy using immune checkpoint inhibitors (ICIs). Of the endocrine irAEs, pituitary and thyroid irAEs are most frequently observed, followed by primary adrenal insufficiency, type 1 diabetes mellitus and hypoparathyroidism. Notably, pituitary irAEs and type 1 diabetes mellitus can be lethal if overlooked, potentially leading to adrenal crisis and diabetic ketoacidosis, respectively.
View Article and Find Full Text PDFAssessment of the use of long-acting insulin in management of DKA in pediatrics: randomized controlled trial.
Ann Pediatr Endocrinol Metab
January 2025
Department of Pediatrics, Mansoura university., Dakahlyia, Egypt.
Purpose: We evaluated the effectiveness of starting long-acting insulin early during managing diabetic ketoacidosis (DKA) in pediatric patients.
Methods: Patients with DKA were randomly assigned to receive either traditional DKA management protocol or concurrent administration of subcutaneous (SC) long-acting insulin alongside intravenous insulin during DKA treatment. The primary outcomes were the duration of insulin infusion and the adverse effects of the intervention, mainly hypoglycemia and hypokalemia.
Life-threatening dapagliflozin-associated euglycaemic diabetic ketoacidosis in a postoperative patient.
BMJ Case Rep
January 2025
Kasturba Medical College Mangalore, Mangalore, Karnataka, India
Euglyceamic diabetic ketoacidosis (EuDKA) is an uncommon but serious diabetes mellitus complication associated with risk factors such as fasting, surgery, pregnancy and, more recently, the use of sodium-glucose cotransporter-2 inhibitors (SGLT2i). This case is of a woman with type 2 diabetes and hypertension in her 50s who underwent an incarcerated umbilical hernia repair and abdominoplasty. Two days after discharge, she was readmitted with nausea, vomiting, loss of appetite, low-grade fever and breathing difficulty.
View Article and Find Full Text PDFDifferential expression of plasma proteins and pathway enrichments in pediatric diabetic ketoacidosis.
Mol Med
January 2025
Physiology and Pharmacology, Western University, London, ON, Canada, N6A 3K7.
Background: In children with type 1 diabetes (T1D), diabetic ketoacidosis (DKA) triggers a significant inflammatory response; however, the specific effector proteins and signaling pathways involved remain largely unexplored. This pediatric case-control study utilized plasma proteomics to explore protein alterations associated with severe DKA and to identify signaling pathways that associate with clinical variables.
Methods: We conducted a proteome analysis of plasma samples from 17 matched pairs of pediatric patients with T1D; one cohort with severe DKA and another with insulin-controlled diabetes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!